NASA Signs Agreement to Develop Nasal Spray for Motion Sickness

 
From: "[NASA REPORTS]" <list.admin@aus-city.com>
Date: October 12th 2012

Oct 12, 2012

Rachel Kraft Headquarters, Washington
202-358-1100 rachel h kraft@nasa gov

William Jeffs Johnson Space Center, Houston 281-483-5111 william p jeffs@nasa gov

RELEASE: 12-361

NASA SIGNS AGREEMENT TO DEVELOP NASAL SPRAY FOR MOTION SICKNESS

HOUSTON -- NASA's Johnson Space Center in Houston and Epiomed Therapeutics Inc of Irvine, Calif , have signed an agreement to develop and commercialize a NASA-crafted, fast-acting nasal spray to fight motion sickness

Under the Space Act Agreement, Epiomed will formulate the drug, called intranasal scopolamine, or INSCOP Astronauts often experience motion sickness in space As a result, NASA has conducted extensive research into the causes and treatments for the condition Scopolamine is effective and can be administered as a tablet or injected With a precise dosage, the NASA spray formulation has been shown to work faster and more reliably than the oral form

"NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas," said Lakshmi Putcha, developer of the innovative treatment strategy at Johnson

A gel formulation of INSCOP was developed and tested under a Space Act Agreement between Johnson and the Naval Aerospace Medical Research Laboratory in Pensacola, Fla Results from that trial were published in the journal Aviation, Space and Environmental Medicine in April 2010 that suggest INSCOP is a fast-acting and reliable way to prevent and treat motion sickness

The U S Navy is working on an agreement with Epiomed to test the nasal spray NASA and Epiomed will collaborate on clinical trials related to the Federal Drug Administration requirements NASA is transferring sponsorship of future clinical trials and FDA approvals to Epiomed, which will supply the product for use by NASA and others

For more about Johnson's Human Health and Performance Directorate, which developed INSCOP, visit:

http://go nasa gov/RiKclM

For more on NASA and agency programs, visit:

http://www nasa gov

-end-

To subscribe to the list, send a message to: hqnews-subscribe@mediaservices nasa gov To remove your address from the list, send a message to: hqnews-unsubscribe@mediaservices nasa gov



The following information is a reminder of your current mailing list subscription:

You are subscribed to the following list: [list_name]

using the following email: example@example.com

You may automatically unsubscribe from this list at any time by visiting the following URL:

https://aus-city com/cgi-bin/dada/mail cgi/u/NASA_REPORTS/example/example com/

If the above URL is inoperable, make sure that you have copied the entire address Some mail readers will wrap a long URL and thus break this automatic unsubscribe mechanism

You may also change your subscription by visiting this list's main screen:

<[program_url]/list/[list]>

If you're still having trouble, please contact the list owner at:

<mailto:[list_owner_email]>

The following physical address is associated with this mailing list:

[physical_address]

Forward to a Friend
 
  • This mailing list is a public mailing list - anyone may join or leave, at any time.
  • This mailing list is announce-only.

NASA Reports list

Privacy Policy:

Private list